

Special Issue

Vaccination in Neurological Autoimmune Disorders

Message from the Guest Editors

Vaccination has made an undeniable contribution in the prevention of numerous infectious diseases and associated morbidity and mortality, and represents a key pillar of an efficient healthcare system. The relationship between vaccination and autoimmune disease has been questioned for decades, after observing a relationship between Guillain Barré syndrome and the swine influenza vaccine in the 1970s. Cases of vaccination-triggered autoimmune neurological diseases remain rare and poorly understood. On the other hand, autoimmune neurological diseases are often treated with immunosuppressive therapies. Whether vaccines are as effective with each treatment approach needs further clarification. Moreover, recommendation guidelines for vaccination schedules in such patients have been developed for some disorders but remain elusive. The role of this Special Issue is to provide an updated review of current knowledge in the field of vaccination and neurological autoimmune disorders in an attempt to guide practice. We cordially invite you to participate in this Special Issue, based on your extensive knowledge and experience in the field.

Guest Editors

Dr. Siddappa Byrareddy

Dr. Mary Rensel

Dr. Gabrielle Macaron

Deadline for manuscript submissions

closed (20 July 2021)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/73718

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).